Advertisement

Trophoblasterkrankungen

  • E. Krampl
  • H. Strohmer

Zusammenfassung

Trophoblasterkrankungen umfassen die komplette und partielle hydatiforme sowie die destruierende invasive Mole, den plazentanahen Pseudotumor und das Chorionkarzinom. Die hydatiforme Mole findet sich in 1 von 1000, das Chorionkarkinom in 2,46 von 100000 Schwangerschaften. Die Unterscheidung in komplette und partielle Mole wird anhand morphologischer und histopathologischer Kriterien sowie aufgrund des Karyotyps getroffen. Die Therapie erfolgt mittels Kürettage oder Hysterektomie.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Albers E, Daneshmand S, Hull A (2001) Placental pathology casebook. Complete hydatidiform mole with coexistent term twin pregnancy. J Perinatol 21: 72–75PubMedCrossRefGoogle Scholar
  2. Azab MB, Pejovic MH, Theodore C et al. (1988) Prognostic factors in gestational trophoblastic tumors: a multivariate analysis. Cancer 62: 585–592PubMedCrossRefGoogle Scholar
  3. Bagshawe KD, Dent J, Webb J (1986) Hydatidiform mole in England and Wales 1973-83. Lancet 2: 673–677PubMedCrossRefGoogle Scholar
  4. Berkowitz RS, Goldstein DP (1995) Gestational trophoblast disease. Cancer 76: 2079–2085PubMedCrossRefGoogle Scholar
  5. Berkowitz RS, Goldstein DP (1996) Chorionic tumors. New Engl J Med 335: 1740–1748PubMedCrossRefGoogle Scholar
  6. Berkowitz RS, Goldstein DP, Bernstein MR (1986) Ten year’s experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 23: 111–118PubMedCrossRefGoogle Scholar
  7. Flam F, Lundstrom V, Petterson F (1991) Medical induction prior to surgical evacuation of hydatidiform mole: Is there a greater risk of persistent trophoblastic disease?. Eur J Obstet Gynecol Reprod Biol 42: 57–60PubMedCrossRefGoogle Scholar
  8. Goldstein DP, Berkowitz RS (1995) Prophylactic chemotherapy of complete molar pregnancy. Semin Oncol 22: 157–160PubMedGoogle Scholar
  9. Goldstein DP, Berkowitz RS, Bernstein MR (1981) Management of molar pregnancy. J Reprod Med 26: 208–212PubMedGoogle Scholar
  10. Hancock BW, Welch EM, Gillespie AM, Newlands ES (2000) A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease. Int J Gynecol Cancer 10: 318–322PubMedCrossRefGoogle Scholar
  11. Homesley HD (1994) Development of single-agent regimens for gestational trophoblastic disease. J Reprod Med 39: 185–192PubMedGoogle Scholar
  12. Homesley HD, Blessing JA, Rettenmaier M, Capizzi RL, Major FJ, Twiggs LB (1988) Weekly intramuscular methotrexate for nonmetastatic gestational trophoblast disease. Obstet Gynecol 72: 413–418PubMedGoogle Scholar
  13. Jauniaux E, Brown R, Snijders RJ, Noble P, Nicolaides KH (1997) Early prenatal diagnosis of triploidy. Am J Obstet Gynecol 176: 550–554PubMedCrossRefGoogle Scholar
  14. Kendall A, Gillmore R, Newlands E (2002) Chemotherapy for trophoblastic disease: current standards. Curr Opin Obstet Gynecol 14: 33–38PubMedCrossRefGoogle Scholar
  15. Kim DS, Moon H, Kim KT, Moon YJ, Hwang YY (1986) Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol 67: 690–694PubMedCrossRefGoogle Scholar
  16. Kohorn El, Goldstein DP, Hancock BW, Kim SJ, Lurain JR, Newlands E, Soper JT, Wong LC, Workshop Report (2000) Combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Heath Organization for Trophoblastic Neoplasia. Report of the Working Committee of the International Society for the Study ofTrophoblastic Disease and the International Gynecologic Cancer Society. Int J Gynecol Cancer 10: 84–88PubMedCrossRefGoogle Scholar
  17. Loret de Mola JR, Goldfarb JM (1995) Reproductive performance of patients after gestational trophoblastic disease. Semin Oncol 22: 193–197Google Scholar
  18. Lurain JR, Casanova LA, Miller DS, Rademaker AW (1991) Prognostic factors in gestational trophoblastic tumors: A proposed new scoring system based on mulitvariate analysis. Am J Obstet Gynecol 164: 611–616PubMedGoogle Scholar
  19. Palmer JR (1994) Advances in the epidemiology of gestational trophoblastic disease. J Reprod Med 39: 155–162PubMedGoogle Scholar
  20. Redline RW, Abdul-Karim FW (1995) Pathology of gestational trophoblastic disease. Semin Oncol 22: 96–109PubMedGoogle Scholar
  21. Sebire NJ, Rees H, Paradinas F, Seckl M, Newlands E (2001) The diagnostic implications of routine ultrasound examination in histologically confirmed early molar pregnancies. Ultrasound Obstet Gynecol 18: 662–665PubMedCrossRefGoogle Scholar
  22. Soper JT (1995) Identification and management of high-risk gestational trophoblastic disease. Semin Oncol 22: 172–84.PubMedGoogle Scholar
  23. Soper JT, Clarke-Pearson D, Hammond CB (1988) Metastatic gestational trophoblastic disease: prognostic factors in previously untreated patients. Obstet Gynecol 71: 338–343PubMedGoogle Scholar
  24. Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond CB (1994) 5-Day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol 54: 76–79PubMedCrossRefGoogle Scholar
  25. Soto-Wright V, Bernstein M, Goldstein DP, Berkowitz RS (1995) The changing clinical presentation of complete molar pregnancy. Obstet Gynecol 86: 775–779PubMedCrossRefGoogle Scholar
  26. Spencer K, Liao AW, Skentou H, Cicero S, Nicolaides KH. Screening for triploidy by fetal nuchal translucency and maternal serum free beta-HCG and PAPP-A at 10–14 weeks of gestation. Prenat Diagn 20: 495–499Google Scholar
  27. Wolf NG, Lage JM (1995) Genetic analysis of gestational trophoblastic disease: a review. Semin Oncol 22: 113–120PubMedGoogle Scholar
  28. WHO Scientific Group (1983) Gestational trophoblastic disease. WHOTech Rep Ser 692Google Scholar
  29. Yedema KA, Verheijen RH, Kenemans P, Schijf CP, Borm GF, Segers MF, Thomas CM (1993) Identification of patients with persistent trophoblastic disease by means of a normal human chorionic gonadotropin regression curve. Am J Obstet Gynecol 168: 787–792PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • E. Krampl
  • H. Strohmer

There are no affiliations available

Personalised recommendations